Get the Stockscreener App
2.60
3.17%
0.08
After Hours:
2.60
Bioline Rx Ltd Adr stock is traded at $2.60, with a volume of 9,885.
It is up +3.17% in the last 24 hours and down -8.77% over the past month.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
See More
Previous Close:
$2.52
Open:
$2.49
24h Volume:
9,885
Relative Volume:
0.53
Market Cap:
$12.61M
Revenue:
$1.41M
Net Income/Loss:
$-9.84M
P/E Ratio:
-1.2145
EPS:
-2.1408
Net Cash Flow:
$-7.85M
1W Performance:
+4.54%
1M Performance:
-8.77%
6M Performance:
+9.24%
1Y Performance:
-31.40%
1-Day Range:
$2.49
$2.60
1-Week Range:
$2.42
$2.60
52-Week Range:
$2.15
$4.56
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.60 | 12.61M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-17 | Upgrade | Maxim Group | Hold → Buy |
| Feb-13-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-12-16 | Downgrade | Maxim Group | Buy → Hold |
| Aug-17-15 | Reiterated | Maxim Group | Buy |
| Jul-27-15 | Reiterated | ROTH Capital | Buy |
| Jun-22-15 | Initiated | JMP Securities | Mkt Outperform |
View All
Bioline Rx Ltd Adr Stock (BLRX) Latest News
BioLineRx Files Form F-1 to Register Resale of 2,023,382 ADSs Linked to August 2026 Warrants - Kalkine Media
$5.6 million could go to BioLineRx (Nasdaq: BLRX) if all warrants are exercised for cash. - Stock Titan
BioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGM - tipranks.com
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Diluted net income available to common stockholders of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
Total revenue of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
BioLineRx, Hemispherian to present GLIX1 data at EANO meeting - Investing.com
BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026 - TipRanks
A drug candidate cut tumor growth and extended survival in mice. Human testing is enrolling. - Stock Titan
Long term debt to total assets ratio of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
Return on equity % of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
BioLineRX Ltd. Sponsored ADR Statistics – HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks
BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks
Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Sahm
BioLineRx stock falls on $3.75M share offering plan - Investing.com India
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 - Sahm
What Could BioLineRx (NASDAQ:BLRX) Reveal as NASDAQ Eyes Results? - Kalkine Media
Why Are Nasdaq, S&P 500 Futures Falling Premarket? NVDA, SKHY, SPCX, TSLA, MRNA, MSTR, PURR, WMT Stocks In Focus - TradingView
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards - TipRanks
Serina Therapeutics: Buy Rating Reiterated, $11 Price Target Maintained on Strong SER-252 Clinical Progress - TipRanks
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline Upside - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Price to sales forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 - Investing.com
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - Barchart.com
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
Enterprise value to revenue forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx reports preclinical data on GLIX1 with PARP inhibitor - Investing.com
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion - TipRanks
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model - Barchart.com
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
A41038 Forecast — Price Target — Prediction for 2027 - TradingView
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
Bioline Rx Ltd Adr Stock (BLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):